United States Patent 10,940,148 Claims & US Patent Landscape: What the Estate Covers, Where It May Be Vulnerable, and How It Impacts Generic Entry
What does US Patent 10,940,148 claim, and which claim elements drive infringement risk?
Insufficient information. The claims text is not provided, and without the actual claim set (independent and dependent claims), a claim-by-claim infringement and validity analysis cannot be completed to a standard required for a patent landscape and risk assessment.
Which patents are co-pending, related, or continuation family members to US 10,940,148?
Insufficient information. Without the patent’s bibliographic details (title, assignee, applicants, filing dates, priority dates, IPC/CPC classes, and citation set) and without an identified family list, a definitive family-landscape map cannot be produced.
How strong is the US patent 10,940,148 estate based on claim scope, prior art, and prosecution history?
Insufficient information. A strength assessment requires at least: the full claim language, asserted novelty features, prosecution outcomes (including office actions, amendments, and examiner rejections), and cited references. None of these are available here.
When does US Patent 10,940,148 expire, and what exclusivity extensions could delay generic entry?
Insufficient information. Expiration and any term adjustments depend on: earliest non-provisional filing date, patent term adjustment (PTA), any terminal disclaimers, and whether the patent has enforceability-affecting facts. These data are not present.
What Orange Book listings could be affected by US Patent 10,940,148?
Insufficient information. Orange Book linkage requires identifying the drug product(s) and NDA/ANDA numbers tied to the patent via Orange Book “patent #” mappings. No Orange Book context is provided.
How many ANDA Paragraph IV challenges cite or target US Patent 10,940,148?
Insufficient information. To determine Paragraph IV participation, you need: the relevant NDA/ANDA, the listed patent numbers challenged, and court dockets tying the challenged patents to 10,940,148. None is provided.
What litigation impacts exist for US Patent 10,940,148 (district courts, pleadings, settlements)?
Insufficient information. Litigation impact requires a docket-level lookup by patent and/or NDA/ANDA, including asserted patents in complaints and any settlement timelines. No litigation details are supplied.
What formulation, method-of-use, and manufacturing patents overlap with US 10,940,148?
Insufficient information. Without claim content and without the surrounding patent family and related estates (composition, formulation, polymorph, process, and use patents), overlap cannot be accurately characterized.
How does US Patent 10,940,148 compare with competing patents for the same drug or mechanism?
Insufficient information. Comparative landscape requires identifying the drug, mechanism, dosage forms, and key competitors’ patent estates, then mapping common claim themes and differences. None of those anchors are available.
What generic launch scenarios are most exposed if US Patent 10,940,148 is asserted or invalidated?
Insufficient information. Launch risk depends on which claim limitations are essential to the competitive product, the remaining unexpired patents, and whether the patent covers the formulation, method, or manufacturing steps that would be used by generics. The claim set is not provided.
Key Takeaways
Insufficient information to produce a complete and accurate patent-claims and landscape analysis of US Patent 10,940,148.
FAQs
Insufficient information. No claim text or bibliographic/litigation/regulatory linkage details are provided, so the following cannot be answered without fabricating facts.
References
None (no sources cited).
